Regulation of cell proliferation is necessary for immune responses, tissue repair, and upkeep of organ function to maintain human health 1 . When proliferating cells complete mitosis, a fraction of newly born daughter cells immediately enter the next cell cycle, while the remaining cells in the same population exit to a transient or persistent quiescent state 2 . Whether this choice between two cell-cycle pathways is due to natural variability in mitogen signalling or other underlying causes is unknown. Here we show that human cells make this fundamental cell-cycle entry or exit decision based on competing memories of variable mitogen and stress signals. Rather than erasing their signalling history at cell-cycle checkpoints before mitosis, mother cells transmit DNA damage-induced p53 protein and mitogen-induced cyclin D1 (CCND1) mRNA to newly born daughter cells. After mitosis, the transferred CCND1 mRNA and p53 protein induce variable expression of cyclin D1 and the CDK inhibitor p21 that almost exclusively determines cell-cycle commitment in daughter cells. We find that stoichiometric inhibition of cyclin D1-CDK4 activity by p21 controls the retinoblastoma (Rb) and E2F transcription program in an ultrasensitive manner. Thus, daughter cells control the proliferation-quiescence decision by converting the memories of variable mitogen and stress signals into a competition between cyclin D1 and p21 expression. We propose a cell-cycle control principle based on natural variation, memory and competition that maximizes the health of growing cell populations.
Whether this choice between two cell-cycle pathways is due to natural variability in mitogen signalling or other underlying causes is unknown. Here we show that human cells make this fundamental cell-cycle entry or exit decision based on competing memories of variable mitogen and stress signals. Rather than erasing their signalling history at cell-cycle checkpoints before mitosis, mother cells transmit DNA damage-induced p53 protein and mitogen-induced cyclin D1 (CCND1) mRNA to newly born daughter cells. After mitosis, the transferred CCND1 mRNA and p53 protein induce variable expression of cyclin D1 and the CDK inhibitor p21 that almost exclusively determines cell-cycle commitment in daughter cells. We find that stoichiometric inhibition of cyclin D1-CDK4 activity by p21 controls the retinoblastoma (Rb) and E2F transcription program in an ultrasensitive manner. Thus, daughter cells control the proliferation-quiescence decision by converting the memories of variable mitogen and stress signals into a competition between cyclin D1 and p21 expression. We propose a cell-cycle control principle based on natural variation, memory and competition that maximizes the health of growing cell populations.
We investigated how cells decide between different cell-cycle paths by using a stably transduced live-cell reporter of CDK2 activity in non-transformed human mammary epithelial MCF10A cells 2 . After mitosis, newly born daughter cells either increase CDK2 activity for continued proliferation (CDK2 inc ), or decrease CDK2 activity, entering a persistent (CDK2 low ) or transient (CDK2 delay ) quiescent state (G0) (Fig. 1a) . Selection of the CDK2 path is regulated by mitogen/RAS/ MEK/ERK signalling in mother cells 2, 3 , activation of the cyclin D-CDK4 complex 4 , and induction of E2F transcription factors 5 (Fig. 1b) . Here, we explore whether and how natural variability in signalling regulates the selection of different CDK2 paths.
To determine when different steps in the mitogen signalling pathway are needed for daughter cells to enter the next cell cycle, we tested three points in the pathway by either removing mitogens or applying inhibitors of MEK (PD0325901) or CDK4 (palbociclib) in asynchronously cycling cells. When aligning cells in silico by the time of pathway inhibition relative to the end of mitosis, we confirmed that mitogens and MEK had to be inhibited in mother cells to effectively suppress cell-cycle entry in daughter cells 2, 3 (Fig. 1c, d ). By contrast, inhibition of CDK4 suppressed cell-cycle entry until 2.5 h after mitosis (Fig. 1d) . By transiently removing mitogens for 5 h, we further found that a transient loss in mitogen signalling during G2 or G0/G1 phases suppressed the CDK2 inc or CDK2 delay paths, respectively (Extended Data Fig. 1 ). Taken together, these data suggest that a mediator connects mitogen/MEK/ ERK to CDK4 both across mitosis to regulate CDK2 inc cells and during G0 of daughter cells to regulate CDK2 delay cells.
To test whether variable ERK activity in G2 directs daughter cells to the CDK2 inc or CDK2 low path, we established MCF10A cells stably expressing ERK 6 and CDK2 reporters (Supplementary Video 1). Control experiments confirmed that the signal measured by the ERK reporter reflects ERK activity throughout the cell cycle, except for a peak at the onset of mitosis that is not sensitive to MEK inhibition 7 (Extended Data Fig. 2 ). We also note that inhibition of a peak of ERK activity after mitosis did not prevent cell-cycle entry for most CDK2 inc cells (Extended Data Fig. 3a ). When we classified and averaged ERK activity based on the CDK2 paths of daughter cells, ERK activity during the G2 phase of mother cells was indeed higher in CDK2 inc cells than in CDK2 delay or CDK2 low cells ( Fig. 1e and Extended Data Fig. 3b, c) . A calibration in Extended Data Fig. 2e showed that the mean ERK signal difference in G2 between CDK2 inc and CDK2 low cells corresponded to a 1.4-fold difference in levels of cyclin D1 (Fig. 1f for G2 and Extended Data Fig. 3d for G0/G1). Together with the delay between MEK and CDK4 requirement (Fig. 1d) , these data suggest that naturally higher ERK signalling in mother cells may increase cyclin D-CDK4 activity in daughters to promote the CDK2 inc path. However, when we tested how ERK activity in G2 predicts the CDK2 paths of daughter cells using an odds ratio analysis, we found that ERK activity is only partially predictive for the CDK2 path selection (Fig. 1g, left) . As a reference, a blue line depicts an accurate prediction of the bifurcation in CDK2 activity (Extended Data Fig. 3e , see Methods). The partial prediction is probably not a result of noise, since odds ratios were higher for lower concentrations of mitogen stimuli (Fig. 1g , right and Extended Data Fig. 3f ) or times closer to mitosis (Extended Data  Fig. 3g ). Thus, additional variables probably regulate CDK2 path selection.
We considered whether such an additional regulatory mechanism might be the DNA damage/p53 signalling pathway 8, 9 , since DNA damage is known to occur naturally during DNA replication 10 and high levels of p53-regulated p21 are correlated with cells exiting the cell cycle 2 .
To determine whether p53 and p21 signals in mother cells are correlated with the CDK2 paths of daughter cells, we used live-cell analysis of MCF7 cells that had p53 and p21 tagged with different fluorescent proteins at their endogenous loci 11 . Although MCF7 is a breast cancer cell line, it has intact CDK4-dependent cell-cycle regulation 12 . Notably, when we averaged time courses of p53 and p21 expression based on the CDK2 paths of daughter cells, both protein expression levels were higher before mitosis in cells on the CDK2 low and CDK2 delay paths compared to the CDK2 inc path (Fig. 2a, b and Extended Data Fig. 4a ). This suggests that p53 signalling in mother cells, along with ERK signalling, is contributing to the cell-cycle decision by daughter cells.
We next tested in MCF10A cells whether p53 has a causal role in CDK2 path selection by knockout and short interfering RNA (siRNA) knockdown of p53, and observed an increase in the number of daughter cells taking the CDK2 inc path (Extended Data Fig. 4b, c) . Conversely, direct activation of p53 signalling in mother cells by transient incubation with nutlin-3 or tenovin-6 for 1 h triggered a marked reduction in the CDK2 inc path in daughter cells ( Fig. 2c and Extended Data Fig. 4d ).
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This p53-mediated suppression of the CDK2 inc path was absent in p21 knockout (CDKN1A −/− ) cells (Extended Data Fig. 4e ). We further induced exogenous DNA double-stranded breaks in S or G2 phase using a 20-min pulse of neocarzinostatin (NCS), and confirmed that added DNA damage leads to a checkpoint-mediated delay that increases the duration of the S/G2/M phase 13 (Extended Data Fig. 4f ). Notably, the added DNA damage in mother cells also suppressed the CDK2 inc path in daughter cells ( Fig. 2d and Extended Data Fig. 4g ). Taken together, these experiments argue for a causal link from DNA damage and p53 signalling in mother cells to CDK2 path selection in daughter cells.
We next asked whether residual DNA damage in daughter cells 14 suppresses the CDK2 inc path as previously proposed 15, 16 . We measured phosphorylated histone H2AX (γ H2AX) and 53BP1 puncta as markers for DNA damage (Extended Data Fig. 5a-d ) and pursued several lines of investigation to test this hypothesis. By fixing cells at the end of live-cell experiments and mapping each fixed cell back to its own live-cell trace, we detected γ H2AX puncta primarily before mitosis but not in the (1) Letter reSeArCH
G0/G1 phase of daughter cells that had passed through mitosis (Fig. 2e) . In addition, a pulse of NCS in mother cells significantly increased both γ H2AX and 53BP1 puncta before but not after mitosis (Fig. 2e) . To compare γ H2AX signals between CDK2 inc and CDK2 low cells, we classified daughter cells by CDK2 paths starting 2 h after mitosis (Extended Data Fig. 5e ). The time course of γ H2AX signals showed similarly low levels of γ H2AX for both CDK2 paths, with an expected increase in γ H2AX puncta in CDK2 inc cells during the S phase (Extended Data Fig. 5f ). To further classify cells immediately after mitosis, we used a marker that distinguished hypo-and hyperphosphorylated Rb protein (hypo-and hyper-Rb; Ser807/811), corresponding to active and inactive E2F transcription (Extended Data Fig. 5g, h ). Both γ H2AX and 53BP1 puncta between hypo-and hyper-Rb cells were not significantly different in G0/G1 phase at different times after mitosis, even in cells that received an NCS pulse in mother cells ( Fig. 2f and Extended Data Fig. 5i, j) . Moreover, inhibition of the DNA damage sensors ATR (ATM-and Rad3-related), ATM (ataxiatelangiectasia mutated) or DNA-PK (DNA-dependent protein kinase) in early G0/G1 did not result in an increase in CDK2 inc path selection (Extended Data Fig. 6a ). Finally, kinetic measurements of p21 in G0/G1 of MCF7 cells in response to an NCS pulse showed a 3 h delay between the pulse and the resulting increase in p21 (Extended Data Fig. 6b ), further arguing against a direct role of residual DNA damage after mitosis in acutely regulating the expression of p21 and regulating CDK2 inc path selection. Taken together, these experiments suggest that a DNA damage signalling response rather than DNA damage itself persists through mitosis to suppress CDK4, Rb-E2F and the CDK2 inc path. The convergence of p53 and ERK signalling onto the same cell-fate decision raised the intriguing question of whether mitogen and stress signalling compete directly. To test this hypothesis, we measured CDK2 activity in MCF10A cells after titration of mitogen and DNA damage stimuli. Titration of NCS pulses and of mitogen levels had opposing and graded effects on cell-cycle entry in daughter cells (Fig. 3a, b) . Notably, higher mitogen levels reversed the effect of an NCS pulse in mother cells on the CDK2 paths of daughter cells (Fig. 3c) . We observed a similar compensatory effect against a G2-phase NCS pulse when we incubated cells with different mitogen levels only in mother cells ( Fig. 3d and Extended Data Fig. 7a ). Thus, mitogen and DNA damage-mediated p53 signalling in G2 compete to control the Cdk2 inc and Cdk2 low paths of daughter cells. To investigate the competition mechanism, we used live-cell imaging to select daughter cells in which mitogen signalling was inhibited for 5 h during the late G2 and M phases of mother cells, and then performed immunostaining or RNA fluorescence in situ hybridization (FISH) in the G0/G1 phase of daughter cells to measure protein or mRNA levels, respectively (Extended Data Fig. 7b ). Consistent with a separation of the two pathways, we found that mitogen withdrawal and MEK inhibition reduced levels of hyper-Rb as well as cyclin D1 mRNA (CCND1) and protein without altering p21 mRNA (CDKN1A) or protein levels in daughter cells (Fig. 3e and Extended Data Fig. 7c-e) . Since cyclin D1 protein is short-lived and the half-life of CCND1 mRNA is over 3 h (Extended Data Fig. 7f, g ), this suggests that CCND1 mRNA is a likely mediator of the long-lasting effect of mitogen signalling in mother cells that regulates the CDK2 inc path of daughter cells. To investigate which mediator may transmit DNA damage signals, we applied an NCS pulse in mother cells and observed a reduction in levels of hyper-Rb as well as increased levels of p53 protein and p21 mRNA (CDKN1A) and protein, while we observed no change in p53 (TP53) and CCND1 mRNA levels in daughter cells (Fig. 3f, g and Extended Data Fig. 8a-d) . We further found that p53 protein probably mediates the transmission of DNA damage signalling in mother cells to daughter cells, as the half-life of p21 (CDKN1A) mRNA and protein was short (approximately 1 h) and the half-life of p53 protein was greatly increased to over 7 h when cells experienced DNA damage 17 (Extended Data Fig. 8e-g ). Using siRNA knockdown and the dihydrofolate reductase (DHFR) and trimethoprim (TMP) protein stabilization system 18 to reduce and increase protein expression levels, respectively, we also directly confirmed that cyclin D1 promotes and p21 inhibits proliferation (Extended Data Fig. 9 ). Together, these results suggest that variable mitogen and DNA damage signalling in mother cells mediate sustained increases in CCND1 mRNA and p53 protein across mitosis (Fig. 3h) to regulate short-lived cyclin D1 and p21 protein levels, which in turn regulate CDK2 inc path selection in daughter cells. Mitogen and stress signalling originating in daughter cells then continue to regulate cyclin D1 and p21 levels and the path selection between CDK2 delay and CDK2 low during G0 and G1 phases ( Fig. 1e and Extended Data Fig. 3d) .
We next determined how variable expression levels of cyclin D1 and p21 control the bimodal phosphorylation of Rb and CDK2 path selection. As expected, high levels of p53 and p21 were closely correlated with the CDK2 low path (Fig. 4a, b) . Contrary to expectations, nuclear cyclin D1 levels were higher in CDK2 low than in CDK2 inc cells (Fig. 4c) . However, p21 has been shown to mediate both the nuclear import 19, 20 and stabilization 21, 22 of cyclin D1 protein, suggesting that higher levels of cyclin D1 observed in CDK2 low cells might be an indirect effect of high p21 levels. As has been proposed previously 21 , it could be the relative level of cyclin D1 compared to p21 that controls CDK4 and E2F activation. To test for a potential stoichiometric relationship between cyclin D1 and p21, we calibrated antibodies against cyclin D1 and p21 by constructing an siRNA-resistant cyclin D1-p21 fusion construct that allowed us to normalize the respective two immuno fluorescence intensities in cells lacking endogenous cyclin D1 and p21 (Fig. 4d and Methods). We first confirmed that the relative levels of cyclin D1 are higher than that of p21 in CDK2 inc cells (Extended Data Fig. 10a ). We then measured levels of cyclin D1 and p21 and determined whether a cell is in the hypo-or hyper-Rb state (Extended Data Fig. 10b, c) . Notably, cells in G0/G1 were only hyper-Rb when they had a stoichiometric excess of cyclin D1 over p21 protein, while almost none were hyper-Rb when cyclin D1 levels were lower than that of p21 in MCF10A as well as in HUVEC (endothelial cells), RPE1 (epithelial cells) and HS68 (foreskin fibroblasts) cells (Fig. 4e and Extended Data Fig. 10d ). Finally, we confirmed that CDK2 inc and CDK2 low cells had almost exclusively hyper-Rb and hypo-Rb, respectively (Fig. 4f) , arguing that CDK4 activation, Rb-regulated E2F induction, and CDK2 activation represent a closely linked bifurcation in cell fate that is controlled by whether or not the cyclin D1/p21 ratio is greater than 1.
We considered that the steep concentration dependence between the cyclin D1/p21 ratio and hyper-Rb might be the result of cyclin D1 binding and activating CDK4, with p21 functioning as a stoichiometric inhibitor that binds cyclin D1-CKD4 complexes and suppresses CDK4 activity (Fig. 4g) . Such a stoichiometric inhibition mechanism predicts ultrasensitive activation of CDK4 if p21 has high affinity for cyclin D1-CDK4 complexes 23 . Our model calculations showed a steep increase in ultrasensitivity when the concentration of p21 is increased (Fig. 4h) . Consistent with the model predictions, our experimental data showed strong ultrasensitivity in the stoichiometric regulation of CDK4 by cyclin D1 and p21, with a Hill coefficient that increased from 4 to 10 over a fivefold increase in the level of p21 (Fig. 4i) . This is likely to be a general regulatory principle for CDK4 activation as we found the same increased ultrasensitivity with p21 concentration in other cell types (Extended Data Fig. 10e) . Thus, E2F induction and CDK2 path selection are controlled by ultrasensitive activation of CDK4 resulting from stress-regulated p21 stoichiometrically inhibiting mitogenregulated cyclin D1-CDK4.
Together, our study argues for a proliferation control system based on (i) natural variation in stress and mitogen signalling in mother cells; (ii) memories of both signals lasting through mitosis to daughter cells; and (iii) molecular competition between stress and mitogen signalling in daughters. This control system selectively promotes proliferation of daughter cells which have experienced lower DNA damage stress and higher mitogen signalling in mother cells. In a situation in which organisms need to generate a fixed number of new cells, for example, during wound healing, a selection mechanism based on relative lower previous stress can maximize the health of newly generated cells. Finally, cancer progression may rely on mutations that reduce this protective molecular competition between cyclin D1 and p21, since many of the upstream regulators of cyclin D1 and p21, such as RAS and p53, respectively, are among the most prominent oncogenes and tumour suppressors in human cancers 24 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
Letter reSeArCH

MethOdS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cell culture. MCF10A cells (ATCC, CRL-10317) were cultured in phenol redfree DMEM/F12 (Invitrogen) supplemented with 5% horse serum, 20 μ g ml
EGF, 10 μ g ml −1 insulin, 0.5 μ g ml −1 hydrocortisone, 100 ng ml −1 cholera toxin, 50 U ml −1 penicillin, and 50 μ g ml −1 streptomycin. For mitogen withdrawal experiments, cells were washed three times and then incubated with GM-GFS medium (DMEM/F12 supplemented with 0.3% BSA, 0.5 μ g ml −1 hydrocortisone, 100 ng ml −1 cholera toxin, 50 U ml −1 penicillin, and 50 μ g ml −1 streptomycin). HUVEC cells (Lonza, C2519A) were cultured in EGM2 (Lonza) supplemented with the bullet kit (Lonza). RPE1 cells (ATCC, CRL-4000) were cultured in phenol red-free DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum and 0.01 mg ml −1 hygromycin B (Invitrogen). HS68 cells (ATCC, CRL-1635) were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum. MCF7 cells (ATCC, HTB-22) were culture in RPMI-1640 (Invitrogen) supplemented with 10% fetal bovine serum. These cell lines were used without further authentication. All cell lines tested negative for mycoplasma. Antibodies and reagents. PD0325901and palbociclib were obtained from Selleckchem. Nutlin-3, tenovin-6, KU-60019, AZ-20, and NU-7441 were from Cayman. Rabbit anti-phospho-Rb (Ser807/811) (8516), rabbit anti-phospho-Rb (Ser807/811) pre-conjugated with Alexa 647 (8974), rabbit anti-p21 (2947), rabbit anti-p53 (2527), rabbit anti-53BP1 (4937) and rabbit anti-phospho-H2AX (9718) were from Cell Signaling Technology. Mouse anti-p21 (556430) was from BD Pharmingen, mouse anti-phospho-H2AX (05-636) was from EMD Millipore, and rabbit anti-cyclin D1 (RM-9104-S0) was from Thermo Scientific. Actinomycin D, cycloheximide and NCS were from Sigma-Aldrich. Constructs and stable cell lines. pPBbsr2-EKAR-NLS, pCSII-histone 2B (H2B)-mTurquoise, pCru5-DHFR-mCherry-p21, and pCSII-DHB (amino acids 994-1087)-mVenus or mCherry were described previously 2, 7 . For pLenti-p21-cyclinD1-IRES-mTurquoise, siRNA-resistant p21 and cyclin D1 were synthesized and cloned into -mTurquoise using Gibson cloning. Geminin (amino acids 1-110) 25 fused to mCherry was cloned into pLenti-IRES-puro. pCru5-DHFR-mCherry-cyclin D1 was cloned into pCru5-IRES-puro. To generate stable cell lines, construct containing ERK sensor within the piggyback transposon was introduced into cells by FugeneHD (Promega) and integrated using the piggyback transposase 26 . Lentiviral constructs were introduced into cells by viral transduction. Odds ratio analysis. Odds ratios were calculated based on averaged ERK activity measured in G2 phase (− 6.5 to − 1 h relative to mitosis). Integrated ERK activity during this time window was rank ordered in 10% bins. CDK2 activity was measured 10 h after mitosis for each cell in the 10 groups of cells for each ranked ERK activity bin. The fraction of cells in each of the 10 bins with a CDK2 activity > 1, 10 h after mitosis (mostly CDK2 inc cells) was then measured. The fractional parameter (fraction of cells that re-enter the cell cycle for a given relative ERK activity in mother cells) is defined as F(erk); erk is the bin parameter (from 1 to 10).
An odds ratio of 1 is random. The reason for the odds ratio limit of 1:8 and 8:1 in the figure is the high probability that pairs of daughter cells take the same path 91% of the time when pairs of daughters from different mothers take the same path only 56% of the time (Extended Data Fig. 3f ). This limits the odds ratio to 8:1 for the prediction by mother cells since daughter cells will occasionally experience variable signals that sets them on different paths. = / / / = . Odds ratio limit (91% 9%) (56% 44%) 8 0
Immunofluorescence. Cells were fixed by adding 4% paraformaldehyde at a ratio of 1:1 to culture medium (final 2% paraformaldehyde) for 15 min. Then, cells were washed three times in PBS, followed by incubation in permeabilization/ blocking buffer with 0.1% Triton X-100, 10% FBS, 1% BSA and 0.01% NaN 3 for 1 h, and stained overnight at 4 °C with primary antibodies. Primary antibodies were visualized using a secondary antibody conjugated to Alexa Fluor-555, Alexa Fluor-568 and Alexa Fluor-647. For EdU staining, cells were treated with 10 μ M EdU for 15 min and fixed and processed according to manufacturer's instructions (Invitrogen, C10356). RNA FISH and analysis. RNA in situ hybridization was carried out using the Affymetrix Quantigene ViewRNA ISH cell assay as specified in the user manual. Custom probes were designed to target E2F1, TP53, CDKN1A and CCND1. In brief, cells were plated in a 96-well glass plate (Cellvis P96-1.5H-N) that was prehybridized with collagen (Advanced BioMatrix, 5005-B) 1:100 in PBS overnight. At the time of fixing, cells were fixed with 4% paraformaldehyde for 15 min and dehydrated overnight using 75% ethanol. After rehydration in PBS for 10 min, the cells were permeabilized with 0.2% Triton X-100 for 15 min at room temperature, and then treated for probe hybridization, amplification, and labelling with Alexa Fluor 555. Cells were then incubated with Hoechst (1:10,000 in PBS) for 10 min, washed three times with PBS, and left in PBS for imaging. For the cases in which immunofluorescence was to be additionally performed, after imaging the FISH signal, cells were incubated with the ViewRNA wash buffer as specified in the user manual to remove the probes and allow for measurement of other fluorophores with a Texas Red filter cube. For RNA FISH measurements, cells were segmented for their whole cell regions by using an area that encompasses the nucleus and reaches out as far as 50 μ m outside of the nuclear mask while preventing overlap with neighbouring cells. A mask of FISH puncta was generated by top hatfiltering raw images with a circular kernel of radius 4 μ m and thresholding absolute intensity. The RNA puncta parameter represents an average of the number of pixels in whole cell regions. siRNA transfection. siRNA was transfected into MCF10A cells using Dharmafect 3 (Thermo Scientific) according to the manufacturer's instructions. The following siRNAs were used: control (Dharmacon, D-001206-14-05), p53 (Dharmacon, LU-003329-00-0002), p21 (Dharmacon, L-003471-00-0005), cyclin D1 (Dharmacon, M-003210-05-0005), cyclin D2 (Dharmacon, LU-003211-00-0002), and cyclin D3 (Dharmacon, MU-003212-02-0002) siRNA pools at final concentration of 20 nM. 6 h after transfection, cells were washed with full growth medium and then imaging was immediately started. Cells were only considered if they went through one mitosis within the imaging period. Cyclin D1 and p21 antibody calibration. After knocking down endogenous cyclin D1 and p21, MCF10A cells stably expressing siRNA-resistant cyclin D1-p21-IRESmTurquoise were selected using mTurquoise expression for the analysis. Plain MCF10A cells (mTurquoise-negative cells) were used for background subtraction. Modelling. We calculated the steepness of CDK4 activation by cyclin D1 assuming that p21 functions as a stoichiometric inhibitor of the cyclin D1-CDK4 complex. Free CDK4, cyclin D1 and p21, are represented as CDK4, cycD and p21. Total CDK4 in the equation is CDK4tot, total cyclin D1 is cycDtot, total p21 is p21tot, active CDK4-cyclin D1 is CDK4_cycD, and inactivated CDK4-cyclin D1-p21 is CDK4_cycD_p21, as shown schematically in Fig. 4g . The calculations are based on equilibrium binding:
The activation step of CDK4 can be described as (cycD × CDK4 = K1 × CDK4_ cycD):
The inactivation step of CDK4 and cyclin D complex can be described as:
2 Using equation (4), we eliminate the variable 'CDK4_cycD_p21' in equation (2) yielding:
Since p21 increased the affinity between cyclin D and CDK4 by about 35 times 19 , we set K 2 to be 35 times smaller than K 1 . We also assume that the phosphorylation of Rb cooperatively increases with CDK4 activity and used equation (5) to generate the plots in Fig. 4h (cooperativity of 2 between CDK4_cycD and the triggering of Rb hyperphosphorylation). Image analysis. We developed a custom MATLAB pipeline for analysed image data as described below. Segmentation. The nuclei of cells were segmented, either by using Hoechst staining for fixed-cell imaging or ERKAR-NLS or H2B-mTurquoise for livecell imaging. For DHB-mVenus measurements, cells were segmented for their cytoplasmic regions by spatially approximating a ring with an inner radius 2 μ m outside of the nuclear mask and an outer radius a maximum of 10 μ m outside the nuclear mask. Regions within 10 μ m of another nucleus were excluded. Regions
Letter reSeArCH with pixel intensities indistinguishable from background (discussed below) were also excluded. Signal measurement. For each channel, global background subtraction was used to measure all immunofluorescence and fluorescent protein intensities as follows: the nuclear mask was dilated by 50 μ m and the background for the image was calculated as the median pixel intensity of all non-masked pixels. DNA content was calculated as integrated nuclear Hoechst intensity. The EdU signal was calculated as the mean nuclear EdU intensity. Nuclear DHB-mVenus immunfluorescence signals were calculated as median nuclear intensity, as the signal was often excluded from the nucleoli. Cytoplasmic DHB-mVenus signals were calculated as the median intensity within the cytoplasmic ring. DHB-mVenus translocation was calculated as the ratio of cytoplasmic signal over the nuclear signal. Throughout this study, CDK2 activity refers to DHB-mVenus translocation. For nuclear γ H2AX puncta measurement, a foreground mask of γ H2AX puncta was generated by top hatfiltering the raw image with a circular kernel of radius 4 μ m and thresholding on absolute intensity. γ H2AX puncta was calculated as the number of foreground pixels within a given nucleus region. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design
Sample size
Describe how sample size was determined.
No statistical method was used to predetermine sample size.
Data exclusions
Describe any data exclusions.
Any failed experiments were excluded mostly due to failure of environmental chamber (Co2 or temperature). Whether the experiments was failed or not determined based on control experiments such as Cdk2 activity behavior.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The experiments were not randomized. Since we tested different conditions in a 96 well plate using fully automated microscopy, we think it is not relevant to our study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All analyses were done by automatic analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
